-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunityBio Q3 net loss more than doubles to $184.57 million

PUBT·11/09/2026 12:33:43
Listen to the news
ImmunityBio Q3 net loss more than doubles to $184.57 million
  • ImmunityBio’s third-quarter 2026 net loss attributable to common stockholders more than doubled year over year to $184.55 million.
  • Net product revenue rose 53% to $48.7 million year over year; the first-nine-month 2026 figure climbed 92% to $143.6 million.
  • The FDA expanded ANKTIVA’s label in October to include adults with BCG-unresponsive nonmuscle-invasive bladder cancer with papillary-only tumors.
  • ANKTIVA’s trial in BCG-naïve bladder cancer met its primary endpoint, keeping a supplemental approval application on track for submission this quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109683136) on November 09, 2026, and is solely responsible for the information contained therein.